Update (9:34 a.m.): Updated with Wednesday market open information.
The stock was up 0.24% to $55.43 at 9:33 a.m. on Wednesday.
Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.
Glaxo was boosted Friday after its HIV joint-venture filed an application in the U.S. and EU for a new combination tablet, in a continued push for dominance in the field